Literature DB >> 1306522

D2 dopaminergic receptors: normal and abnormal transduction mechanisms.

L Caccavelli1, D Cussac, I Pellegrini, V Audinot, P Jaquet, A Enjalbert.   

Abstract

Dopamine receptors of D2 type present on lactotroph cells are coupled to a large series of transduction mechanisms. Beside their negative coupling with adenylate cyclase, they are also coupled with potassium and calcium channels, leading to a decreased intracellular calcium concentration. In addition, D2 dopamine receptors also modulate phospholipase activities. Dopamine inhibits inositol phosphate production, through two distinct mechanisms. One of them could represent a direct negative coupling with phospholipase C. All these transduction mechanisms of the D2 dopamine receptors implicate G proteins sensitive to pertussis toxin. In contrast, these receptors are negatively coupled to phospholipase A2 through G proteins insensitive to this toxin. Both isoforms of the D2 dopamine receptor, generated by alternate splicing of a single gene, are present in lactotroph cells. After transfection in CH4C1 cells the two isoforms are coupled with adenylate cyclase while only the shortest isoform appears negatively coupled to phospholipase C. Functional D2 dopamine receptors are present in human prolactinomas. Resistance to bromocriptine therapy is associated with a decreased density of these receptors in the tumor. In addition, the ratio of the two receptor isoforms (measured by PCR) is different in responsive and resistant tumors. Furthermore, the activity of Gi/Go proteins coupled to adenylate cyclase appears also affected in resistant tumors. Resistance to bromocriptine therapy appears thus to involve multiple changes at the different levels of the multiple mechanisms of action of dopamine on lactotroph cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306522     DOI: 10.1159/000182494

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  6 in total

1.  Dopamine (D2) receptor regulation of intracellular calcium and membrane capacitance changes in rat melanotrophs.

Authors:  A K Lee
Journal:  J Physiol       Date:  1996-09-15       Impact factor: 5.182

Review 2.  Molecular basis of pituitary oncogenesis.

Authors:  M Tada; H Kobayashi; T Moriuchi
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 4.  Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Authors:  Annamaria Colao; Rosario Pivonello; Carolina Di Somma; Silvia Savastano; Ludovica F S Grasso; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

5.  The Inhibitory Effect of Selected D2 Dopaminergic Receptor Agonists on VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New Therapy in Ophthalmic Diseases.

Authors:  Natalia Kasica; Anna Święch; Katarzyna Saładziak; Jerzy Mackiewicz; Maciej Osęka
Journal:  Cells       Date:  2022-04-02       Impact factor: 6.600

6.  The therapeutic effect of bromocriptine in combination with spironolactone in patients with primary aldosteronism: a hypothesis generating pilot study.

Authors:  Vin-Cent Wu; Che-Hsiung Wu; Ya-Wen Yang; Kuo-How Huang; Chia-Hui Chang; Shao-Yu Yang; Yen-Hung Lin; Kwan-Dun Wu
Journal:  Oncotarget       Date:  2017-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.